“…Oxidative stress, as measured by lipid peroxidation, was found elevated in TRS patients compared to antipsychotic-responsive patients, but its relevance for DSP has not yet been investigated (Medina-Hernández, et al, 2007). Although with conflicting evidence (Elmorsy, Al-Ghafari, Aggour, Khan, & Amer, 2017b;Elmorsy, et al, 2017a;Elmorsy, Elzalabany, Elsheikha, & Smith, 2014;Elmorsy & Smith, 2015), clozapine has shown the ability to counter oxidative stress (Sadowska-Bartosz, et al, 2016;Sommer, et al, 2018), protecting cells against DNA damage (Topak, Ozdel, Dodurga, & Secme, 2018), mitochondrial dysfunction (Tran, et al, 2018), death induced by oxygen radicals (Magliaro & Saldanha, 2009), as well as to correct cortico-striatal redox disturbances in SCZ (Möller, et al, 2013). These preclinical observations suggest that antioxidant properties of clozapine may contribute to its peculiar effectiveness in treating re-emergent unresponsive psychotic symptoms in the event of DSP.…”